What Is Vitiligo? PDF Print E-mail
Wednesday, 04 November 2009 19:07
According to the MayoClinic Staff, Vitiligo (vit-ih-LI-go) is a condition in which your skin loses melanin, the pigment that determines the color of your skin, hair and eyes. Vitiligo occurs when the cells that produce melanin die or no longer form melanin, causing slowly enlarging white patches of irregular shapes to appear on your skin. Exactly why this occurs isn't known.

Vitiligo affects all races, but may be more noticeable and disfiguring in people with darker skin. Vitiligo usually starts as small areas of pigment loss that spread with time. These changes in your skin can result in stress and worries about your appearance. Like Scleroderma, there is no cure for vitiligo.

The goal of treatment is to stop or slow the progression of pigment loss and, if you desire, attempt to return some color to your skin.

Although any part of your body may be affected by Vitiligo, depigmentation usually develops first on sun-exposed areas of your skin, such as your hands, feet, arms, face and lips. Although it can start at any age, Vitiligo often first appears between the ages of 10 and 30.

The natural course of Vitiligo is difficult to predict. Sometimes the patches stop forming without treatment. But, in most cases, pigment loss spreads and can eventually involve most of the surface of your skin.

taken from http://www.flickr.com/photos/40097140@N02/3798426328/ via creative commonsDoctors and scientists have theories as to what causes Vitiligo. It may be due to an immune system disorder. Heredity may be a factor because there's an increased incidence of Vitiligo in some families. Some people have reported a single event, such as sunburn or emotional distress, that triggered the condition. However, none of these theories has been proven as a definite cause of Vitiligo.

Vitiligo is the most likely diagnosis in cases in which there is a progressive depigmentation leading to symmetrically distributed, chalk-white macules on the face, neck, scalp, mucous membranes, or periorificial areas, and not accompanied by any other symptom. This is essentially what differentiates Vitiligo from Scleroderma.

Diffuse scleroderma may result in areas of skin hypopigmentation. However, systemic signs of Scleroderma include essential vasomotor disturbances, such as Raynaud's phenomenon, fibrosis, and abnormalities of the lungs, kidneys, digestive system, and heart.

For more information on Vitiligo, you're welcome to view the MayoClinic's full article here, or visit the Vitiligo Foundation here. The International Scleroderma Network has some excellent links to additional resources on Vitiligo, such as diagnoses, personal stories and more. Similarly, there are many research papers on Vitiligo, one of which you can read here.
 
More articles :

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...

» Sonographic Evaluation of Pediatric Localized Scleroderma Preliminary Disease Assessment Measures

Background: Our earlier work in the ultrasonograpy of localized scleroderma (LS) suggests that altered levels of echogenicity and vascularity can be associated with disease activity. Utrasound is clinically benign and readily available, but can be...

» Systemic Sclerosis (Scleroderma)

Panayiotis G. Vlachoyiannopoulos1November 2001Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by small vessel involvement that leads to tissue ischemia and fibroblast stimulation resulting in accumulation of collagen...

» Lidocaine for Systemic Sclerosis: A Double-blind Randomized Clinical Trial

Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical...

» Unite Against Scleroderma

{gallery}unite{/gallery}

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh